Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 34,116 articles published since 2008
|||| 19 

These are the 34116 published articles about Melanoma that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
101 Editorial After a treatment breakthrough-progress, plateaus, and raising the bar. 2017

Margolin, Kim A. ·Department of Medical Oncology, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California. ·Cancer · Pubmed #28543696.

ABSTRACT: -- No abstract --

102 Editorial Melanoma Surgery: Why Don't We Let the Guidelines Guide Practice? 2017

Kang, Ravinder / Wong, Sandra L. ·Department of Surgery, The Geisel School of Medicine at Dartmouth, The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. · Department of Surgery, The Geisel School of Medicine at Dartmouth, The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. Sandra.L.Wong@hitchcock.org. ·Ann Surg Oncol · Pubmed #28534078.

ABSTRACT: -- No abstract --

103 Editorial Not All BRAF-Mutant Metastatic Colorectal Cancers Are Identical: Distinct Clinical Consequences of 2017

Van Cutsem, Eric / Dekervel, Jeroen. ·Eric Van Cutsem and Jeroen Dekervel, University Hospitals Leuven and KULeuven, Leuven, Belgium. ·J Clin Oncol · Pubmed #28510493.

ABSTRACT: -- No abstract --

104 Editorial The Euromelanoma Campaign. 2017

Moreno Giménez, J C. ·Presidente de Honor de la AEDV. Electronic address: md1mogij@uco.es. ·Actas Dermosifiliogr · Pubmed #28499460.

ABSTRACT: -- No abstract --

105 Editorial The microscope and the endoscope. 2017

Govindaraj, Satish. · ·Am J Rhinol Allergy · Pubmed #28490398.

ABSTRACT: -- No abstract --

106 Editorial The four Ws of skin cancer surveillance in patients with melanoma: Why? Who? When? Where? 2017

Nijsten, T / Wakkee, M. ·Department of Dermatology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. ·Br J Dermatol · Pubmed #28418134.

ABSTRACT: -- No abstract --

107 Editorial Commentary: The quest for an improved risk stratification tool for patients with melanoma. 2017

Ming, Michael E. ·Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. Electronic address: michael.ming@uphs.upenn.edu. ·J Am Acad Dermatol · Pubmed #28411773.

ABSTRACT: -- No abstract --

108 Editorial Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape. 2017

Levine, Oren / Devji, Tahira / Xie, Feng. ·Department of Health Research Methods, Evidence, & Impact, McMaster University, Room H306 Martha Wing, St Joseph's Healthcare Hamilton, 50 Charlton Ave. E. Hamilton, ON L8N 4A6, Canada. · Department of Oncology, McMaster University, Hamilton, ON, Canada. · Father Sean O'Sullivan Research Centre, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada. ·Immunotherapy · Pubmed #28357918.

ABSTRACT: -- No abstract --

109 Editorial From the reproducibility of science to the science of reproducibility. 2017

Arnheiter, Heinz. ·Pigment Cell & Melanoma Research. ·Pigment Cell Melanoma Res · Pubmed #28324639.

ABSTRACT: -- No abstract --

110 Editorial The Rising Incidence of Melanoma and Nonmelanoma Skin Cancer Obliges Us to Persevere With Primary and Secondary Prevention Campaigns. 2017

Sanmartín Jimenez, O. ·Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España. Electronic address: osanmartinj@gmail.com. ·Actas Dermosifiliogr · Pubmed #28318526.

ABSTRACT: -- No abstract --

111 Editorial News from the melanoma sessions of the European Cancer Congress 2017. 2017

Rutkowski, Piotr / Kozak, Katarzyna. ·Department of Soft Tissue/Bone Sarcoma and Melanoma; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, Warsaw, 02-781, Poland. ·BMC Med · Pubmed #28302128.

ABSTRACT: During the European Cancer Congress, the melanoma sessions focused on practice changing trials. Recent developments and approvals in immunotherapy and targeted agents have significantly changed the landscape of melanoma therapy in the metastatic setting and provide great promise for adjuvant and neoadjuvant treatment in high-risk locoregional disease. Perioperative (combined pre- and postoperative) strategies may be extremely beneficial for patients with bulky stage IIIC disease. The long-term results of the European Organisation for Research and Treatment of Cancer (EORTC) 18071 adjuvant trial ipilimumab versus placebo after complete resection of high-risk stage III melanoma, demonstrating improvement in overall survival, has established the reference bar for further trials with postoperative therapy.

112 Editorial [Skin cancers: Soon outside the province of the dermatologist?] 2017

Cribier, B. ·Clinique dermatologique, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg cedex, France. Electronic address: Bernard.cribier@chru-strasbourg.fr. ·Ann Dermatol Venereol · Pubmed #28285681.

ABSTRACT: -- No abstract --

113 Editorial Improving clinical outcomes with pembrolizumab in patients with advanced melanoma. 2017

Kim, Dae Won / Zager, Jonathan S / Eroglu, Zeynep. ·Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA. · Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA. Zeynep.Eroglu@moffitt.org. ·Chin Clin Oncol · Pubmed #28285535.

ABSTRACT: -- No abstract --

114 Editorial Immunotherapy resistance: the answers lie ahead - not in front - of us. 2017

Andrews, Miles C / Wargo, Jennifer A. ·Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX 77030 USA. · Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX 77030 USA. ·J Immunother Cancer · Pubmed #28239464.

ABSTRACT: Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manuscript by Zaretsky and colleagues, mutational events were identified that effectively crippled ongoing immunotherapy responses in patients treated with anti-PD-1 therapy. These results are discussed in the light of other recent and ongoing research efforts exploring both mutational and non-mutational resistance mechanisms, highlighting the critical translational importance of longitudinal tumor sampling.

115 Editorial UV-Radiation: From Physics to Impacts. 2017

Moshammer, Hanns / Simic, Stana / Haluza, Daniela. ·Department for Environmental Health, Center for Public Health, Medical University of Vienna, Vienna 1090, Austria. hanns.moshammer@meduniwien.ac.at. · Institute for Meteorology, University of Natural Resources and Life Sciences, Vienna 1180, Austria. stana.simic@boku.ac.at. · Department for Environmental Health, Center for Public Health, Medical University of Vienna, Vienna 1090, Austria. daniela.haluza@meduniwien.ac.at. ·Int J Environ Res Public Health · Pubmed #28218687.

ABSTRACT: Ultraviolet (UV) radiation has affected life at least since the first life forms moved out of the seas and crawled onto the land. Therefore, one might assume that evolution has adapted to natural UV radiation. However, evolution is mostly concerned with the propagation of the genetic code, not with a long, happy, and fulfilling life. Because rickets is bad for a woman giving birth, the beneficial effects of UV-radiation outweigh the adverse effects like aged skin and skin tumors of various grades of malignancy that usually only afflict us at older age. Anthropogenic damage to the stratospheric ozone layer and frighteningly high rates of melanoma skin cancer in the light-skinned descendants of British settlers in Australia piqued interest in the health impacts of UV radiation. A changing cultural perception of the beauty of tanned versus light skin and commercial interests in selling UV-emitting devices such as tanning booths caught public health experts off-guard. Counseling and health communication are extremely difficult when dealing with a "natural" risk factor, especially when this risk factor cannot (and should not) be completely avoided. How much is too much for whom or for which skin type? How even measure "much"? Is it the (cumulative) dose or the dose rate that matters most? Or should we even construct a more complex metric such as the cumulative dose above a certain dose rate threshold? We find there are still many open questions, and we are glad that this special issue offered us the opportunity to present many interesting aspects of this important topic.

116 Editorial Lymphadenectomy for melanoma: a trade off. 2017

Crowe, Philip. ·Department of Surgery, Prince of Wales Hospital, Sydney, New South Wales, Australia. ·ANZ J Surg · Pubmed #28156063.

ABSTRACT: -- No abstract --

117 Editorial Optimizing Follow-up Assessment of Patients with Cutaneous Melanoma. 2017

Bhutiani, Neal / Egger, Michael E / McMasters, Kelly M. ·Division of Surgical Oncology, The Hiram C. Polk, Jr., MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA. · Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Division of Surgical Oncology, The Hiram C. Polk, Jr., MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA. mcmasters@louisville.edu. ·Ann Surg Oncol · Pubmed #28120134.

ABSTRACT: -- No abstract --

118 Editorial Mitotic figures and the evolving staging of melanoma. 2017

Helm, Thomas N. ·Jacobs School of Medicine, State University of New York at Buffalo, Williamsville, New York. ·J Cutan Pathol · Pubmed #28116802.

ABSTRACT: -- No abstract --

119 Editorial [Treating metastatic melanoma: Risk management]. 2017

Lebbe, C / Robert, C. ·Université Paris-Diderot, Sorbonne-Paris-Cité, APHP services de dermatologie et CIC, hôpital Saint-Louis-Paris, INSERM U976, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: celeste.lebbe@aphp.fr. · Département de médecine, service de dermatologie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris-Sud, 114, rue Édouard-Vaillant, 94800 Villejuif, France. ·Ann Dermatol Venereol · Pubmed #28063593.

ABSTRACT: -- No abstract --

120 Editorial Introduction to the special issue of European Journal of Surgical Oncology: New roads in melanoma management. 2017

Rutkowski, P. ·Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Roentgena Str. 5, 02-781 Warsaw, Poland. Electronic address: piotr.rutkowski@coi.pl. ·Eur J Surg Oncol · Pubmed #28034500.

ABSTRACT: -- No abstract --

121 Editorial New Dermatological Insights in Melanoma Diagnosis and Treatment. 2017

Puig Sardá, S. ·Unidad de Melanoma, Servicio de Dermatología, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, España; Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, España; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, España. Electronic address: spuig@clinic.ub.es. ·Actas Dermosifiliogr · Pubmed #28034368.

ABSTRACT: -- No abstract --

122 Editorial Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma. 2017

de Greef, R / Elassaiss-Schaap, J / Chatterjee, M / Turner, D C / Ahamadi, M / Forman, M / Cutler, D / de Alwis, D P / Kondic, A / Stone, J. ·Merck & Co., Inc, Kenilworth, New Jersey, USA. · Quantitative Solutions, a Certara company, Oss, The Netherlands. · PD-Value, Houten, The Netherlands. ·CPT Pharmacometrics Syst Pharmacol · Pubmed #27653180.

ABSTRACT: Recently, immunotherapy has yielded promising results in several cancer types. Contrary to the established classical chemotherapy-dosing paradigm, a maximum tolerated dose approach does not always produce better clinical outcomes for novel targeted therapies, as their efficacy is frequently robust at pharmacologically active doses below the maximum tolerated dose. Integrated safety and efficacy assessments are needed to inform clinical dose and trial design, and to support an early identification of potentially safe and efficacious combination treatments.

123 Editorial Editorial: Should We Abandon TNM Staging in Favor of Gene Profiles in Node-Positive Melanoma? 2017

Engelhardt, Kathryn E / Wayne, Jeffrey D / Bilimoria, Karl Y. ·Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery and Center for Healthcare Studies, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. · Center for Healthcare Studies, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. · Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. · Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery and Center for Healthcare Studies, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. kbilimoria@nm.org. · Center for Healthcare Studies, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. kbilimoria@nm.org. · Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. kbilimoria@nm.org. · Northwestern Institute for Comparative Effectiveness Research (NICER) in Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. kbilimoria@nm.org. ·Ann Surg Oncol · Pubmed #27638680.

ABSTRACT: -- No abstract --

124 Editorial Sunscreen Use in the Prevention of Melanoma: Common Sense Rules. 2016

Nijsten, Tamar. ·Tamar Nijsten, Erasmus MC, Rotterdam, the Netherlands. ·J Clin Oncol · Pubmed #28056596.

ABSTRACT: -- No abstract --

125 Editorial Dermoscopy in Europe: coming of age. 2016

Bahadoran, P / Malvehy, J. ·Department of Dermatology, Clinical Research Center, Archet Hospital, Nice, France. · Dermatology Department, Melanoma Unit, Hospital Clinic and IDIBAPS, Barcelona, Spain. ·Br J Dermatol · Pubmed #27996126.

ABSTRACT: -- No abstract --

Back · Next